State Street SPDR S&P Pharmaceuticals ETF
XPH
75 hedge funds and large institutions have $224M invested in State Street SPDR S&P Pharmaceuticals ETF in 2019 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 10 increasing their positions, 27 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
25% more funds holding
Funds holding: 60 → 75 (+15)
10% more capital invested
Capital invested by funds: $204M → $224M (+$19.6M)
13.29% less ownership
Funds ownership: 110.25% → 96.97% (-13%)
63% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 27
Top Buyers
Top Sellers
XPH Hedge Fund Activity: Q4 2019 in Review
75 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2019, worth a combined $224M — up 9.6% from $204M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new XPH positions and 5 closed out — a net gain of 15 holders — while 10 added to existing stakes and 27 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $33.7M. The largest seller was JP Morgan Chase, cutting an estimated $44.6M.
- 75 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2019, up from 60 in Q3 2019.
- Funds reported $224M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2019, up 9.6% quarter-over-quarter.
- 20 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2019 and 5 closed out, a net change of +15 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2019 was BNP Paribas Financial Markets, an estimated $33.7M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2019 was JP Morgan Chase, an estimated $44.6M sold.
Based on aggregated 13F filings for Q4 2019.